TOPIC:

Johnson & Johnson

Watch breaking news videos and read news updates about Johnson & Johnson on FOXBusiness.com.

LATEST VIDEOS

Pharma to Benefit From Health-Care Reform

10/14/2009|FOX Business

Pharma to Benefit From Health-Care ReformS&P's Sam Stovall argues health-care reform will benefit pharmaceuticals by increasing customers.

Midday Market Update 10-13-09

10/13/2009|FOX Business

Midday Market Update 10-13-09Goldman loses support, Johnson & Johnson posts earnings, and CIT starts a search for a new leader.

Are Big Stock Returns Still Possible?

10/05/2009|FOX Business

Are Big Stock Returns Still Possible?Ariel Capital Management Vice Chairman Charles Bobrinskoy on the outlook for investing.

Investing Like Warren Buffett

08/04/2009|FOX Business

Investing Like Warren BuffettValidea.com Founder John Reese on how he has turned Warren Buffett's strategy into a model for investing.

Health-Care Providers to Cut Cost Increases?

05/12/2009|Closing Bell

Health-Care Providers to Cut Cost Increases?Rep. John Fleming weighs in on financing the U.S. health care system.

Strong Earnings = Strong Market??

04/14/2009|FOX Business

Strong Earnings = Strong Market??Will positive earnings boost the markets?

J&J vs Merck

04/13/2009|Money for Breakfast

J&J vs MerckPharmaceutical rivalry between J&J and Merck

Wealthiest Foundations

11/18/2008|America's Nightly Scoreboard

Wealthiest FoundationsPower Rankings: The wealthiest foundations.

Running a New Business

08/18/2008|Money for Breakfast

Running a New BusinessNew products for athletes by athletes.

LATEST STORIES

Cavuto: Enjoy the Market's Rally Now

By Managing Editor & Anchor| FOXBusiness| Markets

customers, upgrading their homes. Not that buying more gadgets means we can buy this notion of a turnaround. Not when Johnson and Johnson isn't seeing it. But smart market folks like Edward Yardeni are. He's buying tech. Others buying pretty much

Story|10/14/2009

J&J, Schering-Plough Arthritis Drug Simponi Gets EU Approval

FOXBusiness| Markets

FOXBusiness Simponi, Johnson and Johnson ’s (JNJ) new drug designed to treat arthritis in a once-monthly tablet, has been approved for the treatment of moderate

Story|10/06/2009

Johnson & Johnson Reports Rise in Earnings

By Kathryn Elizabeth Tuggle| FOXBusiness| Markets

& Johnson (JNJ), the health care products maker, reported a 14% rise in profits for the fourth quarter, with earnings of $2.7 billion or 97 cents a share compared to $2.4 billion or 82 cents a share last year.

Story|01/20/2009

How a Windfall Oil Profits Tax Would Hurt You « Emac's Stock Watch

Emac's Stock Watch

Thomson, is 9.7%, one report shows. The average for the S&P 500 is about 8.5%. Not much of a difference. Johnson and Johnson has routinely showed profit margins of about 20%, same for the financials before they got socked due to their

Blog|06/13/2008